- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Authors
Latest:
Electronic Health Record Problem Lists: Accurate Enough for Risk Adjustment?Electronic health record (EHR)-based comorbidity assessment had low sensitivity for identifying major comorbidities and poorly predicted survival. EHR-based comorbidity data require validation prior to application to risk adjustment.
Latest:
Current Evidence and Controversies: Advanced Practice Providers in HealthcareThe authors compare advanced practice providers’ education, training, scope of practice, and quality of care with that of physicians. A framework is essential to promote team-based primary care.
Latest:
Medicare’s Bundled Payment Model Did Not Change Skilled Nursing Facility Discharge PatternsHospital participation in Medicare’s Bundled Payments for Care Improvement model was not associated with changes in number of skilled nursing facility (SNF) partners or in SNF discharge concentration.
Latest:
Prognostic Factors of Mortality Among Patients With Severe HyperglycemiaSepsis, renal impairment with electrolyte imbalance, and low blood pressure were independent prognostic factors of mortality among patients with severe hyperglycemia in the emergency department.
Latest:
Evaluating a Hepatitis C Quality Gap: Missed Opportunities for HCV-Related CareManagement of hepatitis C screening results can be optimized to ensure that patients receive high-quality care, reducing morbidity and costs related to the virus.
Latest:
Do Electronic Medical Records Improve Diabetes Quality in Physician Practices?Policy makers should not expect public sector electronic medical record investments to yield substantial short-term improvements in publicly reported measures.
Latest:
Diabetes and Medicare Competitive Bidding: The "Perfect Storm" for Patient HarmA recent Diabetes Care study found flaws in Medicare's competitive bidding program for diabetes test strips. Two of that study's co-authors discuss the findings and why CMS should suspend the bidding program.
Latest:
The Value of Specialty Pharmaceuticals - A Systematic ReviewThis study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.
Latest:
Assessing Outcomes in Child PsychiatryTwo standardized rating scales appeared to be valid and reliable for use at admission and possibly follow-up in a child psychiatry system of care.
Latest:
Physician Capability to Electronically Exchange Clinical Information, 2011We assessed physicians' capability to electronically share clinical information with other providers and describe variation in exchange capability across states and electronic health record vendors.
Latest:
Effectiveness and Cost-Effectiveness of Diabetes Prevention Among Adherent ParticipantsOver 10 years, among adherent participants, lifestyle intervention and metformin were effective and cost-effective for diabetes prevention compared with placebo.
Latest:
Specialist Participation in Healthcare Delivery Transformation: Influence of Patient Self-ReferralAnalyses of national trends indicate that a considerable proportion of new specialist visits among both Medicare and private insurance beneficiaries are self-referred.
Latest:
Service Setting Impact on Costs for Bevacizumab-Treated Oncology PatientsFor patients with lung or colorectal cancer, bevacizumab treatment patterns and healthcare costs varied by the setting of treatment initiation (physician office vs hospital outpatient).
Latest:
Adherence to Osteoporosis Medications After Patient and Physician Brief Education: Post Hoc Analysis of a Randomized Controlled TrialPost hoc analysis of a randomized controlled trial found that a 1-session educational intervention targeted at patients and primary care physicians did not improve osteoporosis medication adherence.
Latest:
Reports of the Demise of Chemotherapy Have Been Greatly ExaggeratedThe expanding arsenal of targeted and immuno-oncology drugs has unalterably changed the landscape of systemic cancer treatment, but chemotherapy will remain critical for years if not decades to come.
